APA

Moore K. N., Borghaei H., O'Malley D. M., Jeong W., Seward S. M., Bauer T. M., Perez R. P., Matulonis U. A., Running K. L., Zhang X., Ponte J. F., Ruiz-Soto R. & Birrer M. J. (20170911). Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. : Cancer.

Chicago

Moore Kathleen N, Borghaei Hossein, O'Malley David M, Jeong Woondong, Seward Shelly M, Bauer Todd M, Perez Raymond P, Matulonis Ursula A, Running Kelli L, Zhang Xiaoyan, Ponte Jose F, Ruiz-Soto Rodrigo and Birrer Michael J. 20170911. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. : Cancer.

Harvard

Moore K. N., Borghaei H., O'Malley D. M., Jeong W., Seward S. M., Bauer T. M., Perez R. P., Matulonis U. A., Running K. L., Zhang X., Ponte J. F., Ruiz-Soto R. and Birrer M. J. (20170911). Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. : Cancer.

MLA

Moore Kathleen N, Borghaei Hossein, O'Malley David M, Jeong Woondong, Seward Shelly M, Bauer Todd M, Perez Raymond P, Matulonis Ursula A, Running Kelli L, Zhang Xiaoyan, Ponte Jose F, Ruiz-Soto Rodrigo and Birrer Michael J. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. : Cancer. 20170911.